We are monitoring the impact of COVID-19 on APAC Biosimilars Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 1081
Share on
Share on

Asia Pacific Biosimilars Market Research Report – Segmented By Type, Technology, Application and Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2021 to 2026)

Pulished: April, 2021
ID: 1081
Pages: 145

APAC Biosimilars Market Size (2021 to 2026)

As per our analysis, the biosimilars market size in the Asia Pacific is predicted to grow from 1.26 billion in 2021. This value is predicted to grow USD 4.99 billion by 2026 and at a CAGR of 31.60% during the forecast period.

Biosimilars are recognized as among the healthcare industry's most important markets and are seen as an accessible and economical treatment option with rising healthcare costs. Growing economies are seeing extensive development from the challenging medical therapeutic needs in the biosimilar industry. Increasing GDP and healthcare sector spending and demand for an economical therapeutic solution have contributed to this market's growth. Besides, biosimilars find their use in preventing and treating various chronic disorders like diabetes, cancers, cardiovascular diseases, etc. The demand for biosimilars is likely to rise in the coming years.

While Asia-Pacific is the quickest-growing market for biosimilars due to low production costs, skilled and cheap labor availability, slender regulations laid down by governments, there are, however, cost high for manufacturing and sophistication, and the prevalence on the market of economically priced generic drugs, which has come forward as some of the biosimilars market's main constraints.

Biosimilars are a great opportunity; the market will eventually become a large business, irrespective of a slow start. Countries like India, China, and South Korea are providing an enticing opportunity to develop and sell medicines in the region. Besides, these markets are generic-driven, creating a favorable incentive for the development and marketing of biosimilars. Also, the growing initiatives from the government and increasing investment in the healthcare sector in the region are providing lucrative growth opportunities for the region’s market to grow substantially. Large profit-churning blockbuster drugs are expected to lose their patent protection in APAC throughout the forecast period, and biosimilar firms are vigilant in filing marketing rights proposals.

This research report on the APAC Biosimilars Market has been segmented and sub-segmented market into the following categories:

By Product Type:

  • Protein
  • Insulin
  • Human Growth Hormones
  • Granulocyte Colony-stimulating Factor (G-CSF)
  • Interferons
  • Recombinant Glycosylated Proteins
  • Erythropoietin
  • Monoclonal Antibodies
  • Follitropin
  • Recombinant Peptides
  • Glucagon

By Technology:

  • Mass Spectroscopy
  • Chromatography
  • Monoclonal Antibody Technology
  • Recombinant DNA Technology
  • Nuclear Magnetic resonance (NMR) technology
  • Electrophoresis
  • Bioassay

By Disease:

  • Oncology Diseases
  • Blood Disorders
  • Growth hormone deficiencies
  • Chronic and autoimmune diseases
  • Others

By Country:

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Thailand
  • Malaysia
  • Vietnam
  • Philippines
  • Indonesia
  • Singapore
  • Rest of APAC

The market for biosimilars in Asian nations is projected to develop significantly in the near future because of the readily available skilled labor, cheaper production costs, and fewer regulatory requirements. China, India, and Korea are all seeing active expansion in the biosimilars industry right now. Biosimilars provide rising Asian nations a significant opportunity to develop indigenous biologics and biotechnology capabilities. Domestic and regional biosimilar producers in Asian developing markets will be able to take the worldwide leader in the near future. Because the number of biosimilar producers in China is rapidly increasing, the Chinese FDA has established and approved biosimilars standards governing China's production, sale, and consumption. The primary drivers driving the market expansion in this area are the rising frequency of chronic diseases such as malignancies and increased investment in research and development efforts by key companies. Chronic diseases such as diabetes, cancer, and rheumatoid arthritis are becoming more common throughout the world, necessitating an ever-increasing demand for biologicals that are inexpensive and accessible in Asia Pacific countries (APAC).

Biosimilars are growing in APAC, and several biotech companies have either opened or are in the process of constructing production facilities to deliver inexpensive medicines to Asian patients. In the research and marketing of biosimilars, China and India are also regarded to be prominent nations. While this type of product has been on the market for decades, the necessary rules and regulations have recently been adopted. The Chinese government has a variety of programs in place to help with biosimilar development and uptake. These include establishing transnational clinical centers, exchanging clinical data globally, expediting the special medication approval procedure, and improving clinical data security. The region's market growth is boosted by an expanding product pipeline and new product releases.

KEY MARKET PLAYERS:

A few notable companies operating in the APAC Biosimilars market are Sandoz International GmbH, Wockhardt Ltd, Hospira, Inc., Teva Pharmaceutical Industries Ltd. Dr. Reddy’s Laboratories, Biocon Limited, Mylan, Inc., Zydus Cadila, Celltrion Inc., Roche Diagnostics, and Cipla Ltd.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 By Type                        

                                5.1.1 Protein     

                                5.1.2 Insulin       

                                5.1.3 Human Growth Hormones

                                5.1.4 Granulocyte Colony-stimulating Factor (G-CSF)       

                                5.1.5 Interferons             

                                5.1.6 Recombinant Glycosylated Proteins             

                                5.1.7 Erythropoietin       

                                5.1.8 Monoclonal Antibodies     

                                5.1.9 Follitropin

                                5.1.10 Recombinant Peptides    

                                5.1.11 Glucagon               

                                5.1.12 Calcitonin              

                5.2 By Technology                          

                                5.2.1 Mass Spectroscopy             

                                5.2.2 Chromatography  

                                5.2.3 Monoclonal Antibody Technology

                                5.2.4 Recombinant DNA Technology       

                                5.2.5 Nuclear magnetic resonance (NMR) technology     

                                5.2.6 Electrophoresis     

                                5.2.7 Bioassay   

                5.3 By Application                           

                                5.3.1 Oncology diseases

                                5.3.2 Blood disorders    

                                5.3.3 Growth hormone deficiencies        

                                5.3.4 Chronic and autoimmune diseases

                                5.3.5 Others      

6. Geographical Analysis                                              

                6.3 Asia-Pacific                 

                                6.1 Introduction              

                                6.2 China            

                                6.3 India              

                                6.4 Japan            

                                6.5 South Korea

                                6.6 Australia      

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental      

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services

                                7.2.5 Competitive Rivalry within the Industry      

8.Market Leaders' Analysis                                          

                8.1 Sandoz International GmbH                

                                8.1.1 Overview

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Wockhardt                 

                8.3 Hospira                        

                8.4 Teva Pharmaceutical Industries                         

                8.5 Dr. Reddy’s Laboratories                      

                8.6 Biocon                          

                8.7 Mylan                           

                8.8 Zydus Cadila                               

                8.9 Celltrion                       

                8.10 Roche Diagnostics                 

                8.11 Cipla                            

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                        

                9.3 Agreements, collaborations and Joint Ventures                          

                9.4 New Product Launches                          

10.Market Outlook and Investment Opportunities                                           

                                               

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Asia-Pacific Biosimilars Market, By Type, From 2021 to 2026 (USD Billion)
  2. Asia-Pacific Protein Market, By Region, From 2021 to 2026 (USD Billion)
  3. Asia-Pacific Insulin Market, By Region, From 2021 to 2026 (USD Billion)
  4. Asia-Pacific Human Growth Hormones Market, By Region, From 2021 to 2026 (USD Billion)
  5. Asia-Pacific Granulocyte Colony-stimulating Factor (G-CSF) Market, By Region, From 2021 to 2026 (USD Billion)
  6. Asia-Pacific Interferons Market, By Region, From 2021 to 2026 (USD Billion)
  7. Asia-Pacific Recombinant Glycosylated Proteins Market, By Region, From 2021 to 2026 (USD Billion)
  8. Asia-Pacific Erythropoietin Market, By Region, From 2021 to 2026 (USD Billion)
  9. Asia-Pacific Monoclonal Antibodies Market, By Region, From 2021 to 2026 (USD Billion)
  10. Asia-Pacific Follitropin Market, By Region, From 2021 to 2026 (USD Billion)
  11. Asia-Pacific Recombinant Peptides Market, By Region, From 2021 to 2026 (USD Billion)
  12. Asia-Pacific Glucagon Market, By Region, From 2021 to 2026 (USD Billion)
  13. Asia-Pacific Calcitonin Market, By Region, From 2021 to 2026 (USD Billion)
  14. Asia-Pacific Biosimilars Market, By Technology, From 2021 to 2026 (USD Billion)
  15. Asia-Pacific Mass Spectroscopy Market, By Region, From 2021 to 2026 (USD Billion)
  16. Asia-Pacific Chromatography Market, By Region, From 2021 to 2026 (USD Billion)
  17. Asia-Pacific Monoclonal Antibody Technology Market, By Region, From 2021 to 2026 (USD Billion)
  18. Asia-Pacific Recombinant DNA Technology Market, By Region, From 2021 to 2026 (USD Billion)
  19. Asia-Pacific Nuclear magnetic resonance (NMR) technology Market, By Region, From 2021 to 2026 (USD Billion)
  20. Asia-Pacific Electrophoresis Market, By Region, From 2021 to 2026 (USD Billion)
  21. Asia-Pacific Bioassay Market, By Region, From 2021 to 2026 (USD Billion)
  22. Asia-Pacific Biosimilars Market, By Application, From 2021 to 2026 (USD Billion)
  23. Asia-Pacific Oncology diseases Market, By Region, From 2021 to 2026 (USD Billion)
  24. Asia-Pacific Blood disorders Market, By Region, From 2021 to 2026 (USD Billion)
  25. Asia-Pacific Growth hormone deficiencies Market, By Region, From 2021 to 2026 (USD Billion)
  26. Asia-Pacific Chronic and autoimmune diseases Market, By Region, From 2021 to 2026 (USD Billion)
  27. Asia-Pacific Others Market, By Region, From 2021 to 2026 (USD Billion)
  28. Japan Biosimilars Market, By Type, From 2021 to 2026 (USD Billion)
  29. Japan Biosimilars Market, By Technology, From 2021 to 2026 (USD Billion)
  30. Japan Biosimilars Market, By Application, From 2021 to 2026 (USD Billion)
  31. China Biosimilars Market, By Type, From 2021 to 2026 (USD Billion)
  32. China Biosimilars Market, By Technology, From 2021 to 2026 (USD Billion)
  33. China Biosimilars Market, By Application, From 2021 to 2026 (USD Billion)
  34. India Biosimilars Market, By Type, From 2021 to 2026 (USD Billion)
  35. India Biosimilars Market, By Technology, From 2021 to 2026 (USD Billion)
  36. India Biosimilars Market, By Application, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample